Connect with us

Hi, what are you looking for?

Clinical Trials

Transforming CLTI Treatment: Giving No-Option Patients New Options

“We’re talking about completely flipping the tables from almost everybody getting an amputation to only a minority of patients getting an amputation by the time you follow them for one year.” – Peter Schneider, MD

Transforming CLTI Treatment: Giving No-Option Patients New Options

“We’re talking about completely flipping the tables from almost everybody getting an amputation to only a minority of patients getting an amputation by the time you follow them for one year.” – Peter Schneider, MD

Medtech executive Dan Rose, CEO of LimFlow, and his clinical investigator, renowned vascular surgeon Peter Schneider, MD join Joe Mullings, Chairman of the Board for TMG360 Media, to discuss promising early data that suggests the current standard for treating Chronic Limb-Threatening Ischemia (CLTI) is undergoing a transformation.

Between CMS naming only four procedural categories as non-elective: trauma, transplant, emerging cardiac and limb salvage, and patients continuing to enroll in the ongoing pivotal trial despite the perceived risk, Rose and Schneider share how the COVID-19 pandemic has fueled this transformation.

By triangulating clinical data, market development, and input from physicians, the CLI subject-matter-experts explain how they are making the procedure easier, faster, and simpler.

As populations continue to age and the rate of chronic diseases such as diabetes, obesity, and renal disease continue to increase, the treatable market for no-option Percutaneous Deep Venous Arterialization (pDVA) is growing. In fact, there were 330,000 new no-option pDVA patients projected in the last year alone. All of which is significantly expanding the PAD market and supercharging BTK growth, representing a potential $1.3 Billion of the estimated $3 Billion US Peripheral Vascular market.

Today, LimFlow is part of a training session at LINC 2021 to discuss the unmet need, the advancement in treatment options, and what the future holds for CLI.

Learn how LimFlow is giving new hope to no-hope CLTI patients in the interview above.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Latest News

BioTechnology

Baleon Capital, a one-year-old venture capital firm started by investment veteran Jon Kaiden, closed its first fund to invest in pre-Series A and Series...

Artificial Intelligence

The Asian digital health market is expected to be worth up to $100 billion by 2025.

Digital Health

Today, BoxGroup is announcing it has beefed up its war chest so that it can be that “first yes” to more companies with the...

CE Mark

Paragonix SherpaPak® CTS is the only commercially available FDA-cleared and CE-marked medical device for heart transportation and the only device to fit small pediatric...

You May Also Like

Artificial Intelligence

Digital Solutions In Healthcare Plug “digital healthcare solutions” into Google, and the results are clear: digital tools have taken the healthcare industry by storm....

Digital Health

The sky’s the limit for HealthTech PR and looking past traditional strategies to nontraditional avenues for engagement will allow agencies to stand out.

COVID-19

In Delray Beach, Florida, an emerging biopharma company, Cyrano Therapeutics, is planning a clinical trial using approved theophylline via a new intranasal pathway of...

Artificial Intelligence

Joe Mullings discusses the Microbot – Liberty robotic platform with Harel Gadot and how a new category of surgical robotics creates a new entry...